HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All Roads For OTC Policy Improvements Lead To User Fees, FDA Suggests

This article was originally published in The Rose Sheet

Executive Summary

In an update on discussions with industry about potential user fees to support FDA's OTC monograph program, CDER officials say "industry and public would suffer" absent new fees.

You may also be interested in...

OTC Monograph Reform May Have To Launch Without User Fees, Senate Sponsor Says

"We believe that we're going to get this done," but "it's possible that ... language authorizing the collection of user fees is not included in this year's appropriation legislation," says Sen. Bob Casey during HELP Committee's confirmation hearing for FDA commissioner nominee Stephen Hahn.

Could Gottlieb Bring Red-Tape Scissors To FDA Sunscreen Review?

FDA Commissioner nominee Scott Gottlieb has been a vocal critic of FDA bureaucracy and excessive data demands that in his view have slowed access to life-saving drugs and medical devices in the US. His expected confirmation as FDA head could offer a new glimmer of hope to sponsors seeking GRASE status for next-generation UV filters, a process that has all but ground to a halt, according to industry advocates.

FDA: ‘Vast Majority’ Of Antibac Soaps Need Reformulation Under Final Rule

FDA/CDER’s Teresa Michele says the “vast majority” of roughly 2,100 consumer antibacterial soaps on the market contain at least one of 19 antimicrobial ingredients banned from OTC use under an FDA final rule. Industry, which suggests the agency is overstating the rule’s impact, is focused on delivering supporting data for three active ingredients still pending before FDA for GRASE use in the category.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts